{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Pemetrexed+%28Chemotherapy%29&page=12", "query": { "intervention": "Pemetrexed (Chemotherapy)", "page": 12 }, "page_size": 10 }, "pagination": { "page": 12, "page_size": 10, "total_count": 381, "total_pages": 39, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Pemetrexed+%28Chemotherapy%29&page=13&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Pemetrexed+%28Chemotherapy%29&page=11&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-14T16:41:38.929Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01958372", "title": "Radiation Therapy, Chemotherapy, and Soy Isoflavones in Treating Patients With Stage IIIA-IIIB Non-Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Adenocarcinoma of the Lung", "Adenosquamous Cell Lung Cancer", "Bronchoalveolar Cell Lung Cancer", "Large Cell Lung Cancer", "Recurrent Non-small Cell Lung Cancer", "Squamous Cell Lung Cancer", "Stage IIIA Non-small Cell Lung Cancer", "Stage IIIB Non-small Cell Lung Cancer" ], "interventions": [ { "name": "soy isoflavones", "type": "DIETARY_SUPPLEMENT" }, { "name": "cisplatin", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "pemetrexed disodium", "type": "DRUG" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "DIETARY_SUPPLEMENT", "DRUG", "RADIATION" ], "sponsor": "Barbara Ann Karmanos Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 11, "start_date": "2014-08", "completion_date": "2019-11-11", "has_results": false, "last_update_posted_date": "2020-11-23", "last_synced_at": "2026-10-14T16:41:38.929Z", "location_count": 5, "location_summary": "Bay City, Michigan • Detroit, Michigan • Lapeer, Michigan + 2 more", "locations": [ { "city": "Bay City", "state": "Michigan" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Lapeer", "state": "Michigan" }, { "city": "Mount Pleasant", "state": "Michigan" }, { "city": "Petoskey", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT01958372" }, { "nct_id": "NCT06865339", "title": "Thoracic Radiotherapy and Inhibition of PD-1 and LAG-3 for Locally Advanced Non-Small Cell Lung Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "NSCLC", "Locally Advanced" ], "interventions": [ { "name": "Cemiplimab", "type": "DRUG" }, { "name": "Fianlimab", "type": "DRUG" }, { "name": "Radiotherapy", "type": "RADIATION" }, { "name": "Platinum Doublet Chemotherapy (PDC)", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Montefiore Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 76, "start_date": "2025-08-07", "completion_date": "2027-08", "has_results": false, "last_update_posted_date": "2026-04-13", "last_synced_at": "2026-10-14T16:41:38.929Z", "location_count": 1, "location_summary": "The Bronx, New York", "locations": [ { "city": "The Bronx", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06865339" }, { "nct_id": "NCT01471197", "title": "Safety and Efficacy Trial of Ipilimumab Versus Pemetrexed in Non-Squamous Non-Small Cell Lung Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lung Cancer - Non Small Cell" ], "interventions": [ { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Pemetrexed", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 9, "start_date": "2012-07", "completion_date": "2013-02", "has_results": true, "last_update_posted_date": "2014-05-12", "last_synced_at": "2026-10-14T16:41:38.929Z", "location_count": 7, "location_summary": "Greenbrae, California • Galesburg, Illinois • Quincy, Illinois + 4 more", "locations": [ { "city": "Greenbrae", "state": "California" }, { "city": "Galesburg", "state": "Illinois" }, { "city": "Quincy", "state": "Illinois" }, { "city": "Mount Sterling", "state": "Kentucky" }, { "city": "Hagerstown", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01471197" }, { "nct_id": "NCT02041533", "title": "An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Stage IV or Recurrent Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 541, "start_date": "2014-03-27", "completion_date": "2022-05-27", "has_results": true, "last_update_posted_date": "2023-03-02", "last_synced_at": "2026-10-14T16:41:38.929Z", "location_count": 36, "location_summary": "Mobile, Alabama • Gilbert, Arizona • Tucson, Arizona + 30 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Stanford", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT02041533" }, { "nct_id": "NCT05410145", "title": "A Study of D3S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "KRAS P.G12C" ], "interventions": [ { "name": "D3S-001", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "D3 Bio (Wuxi) Co., Ltd", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 442, "start_date": "2022-08-03", "completion_date": "2027-04", "has_results": false, "last_update_posted_date": "2026-09-15", "last_synced_at": "2026-10-14T16:41:38.929Z", "location_count": 7, "location_summary": "Orange, California • Palo Alto, California • Denver, Colorado + 4 more", "locations": [ { "city": "Orange", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT05410145" }, { "nct_id": "NCT02838745", "title": "Study of Cytoreductive Surgery and Hyperthermic Intraoperative Chemotherapy With Pemetrexed and Cisplatin for MPM", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Mesothelioma" ], "interventions": [ { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Baylor College of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 7, "start_date": "2016-09", "completion_date": "2019-09-05", "has_results": false, "last_update_posted_date": "2022-03-31", "last_synced_at": "2026-10-14T16:41:38.929Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02838745" }, { "nct_id": "NCT00612677", "title": "Pemetrexed &Oxaliplatin in Patients w Recurrent NSCLCa After Failure to Platinum Based Adjuvant Chem", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lung Cancer" ], "interventions": [ { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2007-06", "completion_date": "2008-01", "has_results": true, "last_update_posted_date": "2017-03-23", "last_synced_at": "2026-10-14T16:41:38.929Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00612677" }, { "nct_id": "NCT00227539", "title": "Positron Emission Tomography in Predicting Response in Patients Who Are Undergoing Treatment With Pemetrexed Disodium and Cisplatin With or Without Surgery for Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lung Cancer" ], "interventions": [ { "name": "cisplatin", "type": "DRUG" }, { "name": "pemetrexed disodium", "type": "DRUG" }, { "name": "adjuvant therapy", "type": "PROCEDURE" }, { "name": "therapeutic conventional surgery", "type": "PROCEDURE" }, { "name": "fludeoxyglucose F 18", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "University of Washington", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 25, "start_date": "2005-07", "completion_date": "2013-11", "has_results": true, "last_update_posted_date": "2017-05-09", "last_synced_at": "2026-10-14T16:41:38.929Z", "location_count": 2, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00227539" }, { "nct_id": "NCT04486833", "title": "Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Carcinoma, Non-Small Cell Lung" ], "interventions": [ { "name": "quaratusugene ozeplasmid", "type": "BIOLOGICAL" }, { "name": "osimertinib", "type": "DRUG" }, { "name": "Platinum-Based Chemotherapy", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Genprex, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 158, "start_date": "2021-09-03", "completion_date": "2029-03", "has_results": false, "last_update_posted_date": "2026-09-16", "last_synced_at": "2026-10-14T16:41:38.929Z", "location_count": 10, "location_summary": "Los Angeles, California • Lone Tree, Colorado • Urbana, Illinois + 7 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Lone Tree", "state": "Colorado" }, { "city": "Urbana", "state": "Illinois" }, { "city": "Lexington", "state": "Kentucky" }, { "city": "Rockville", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04486833" }, { "nct_id": "NCT04964960", "title": "Pembro+Chemo in Brain Mets", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lung Cancer", "Lung Cancer Metastatic", "Brain Cancer", "Cancer" ], "interventions": [ { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Nab paclitaxel", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "John L. Villano, MD, PhD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 3, "start_date": "2022-05-19", "completion_date": "2023-12-19", "has_results": true, "last_update_posted_date": "2025-10-31", "last_synced_at": "2026-10-14T16:41:38.929Z", "location_count": 1, "location_summary": "Lexington, Kentucky", "locations": [ { "city": "Lexington", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT04964960" } ] }